Microdosing a GLP-1: what the evidence search found

What this comes down to

• Wegovy is initiated at 0.25 mg for four weeks and escalated to a maintenance dose of 2.4 mg or 1.7 mg once weekly. The starting dose is a ramp, not a destination.
• Zepbound's label states outright that the 2.5 mg starting dosage is for treatment initiation and is not approved as a maintenance dosage.
• Our September 2026 PubMed search found no trial-tagged GLP-1 microdosing reports. Nine records mention it at all, and not one of them is a trial — six are commentaries or letters, and two are unrelated hits.
• The FDA has received adverse event reports tied to patients measuring and self-administering incorrect doses of compounded semaglutide.

What the approved labels say the doses are

Wegovy starts at 0.25 mg once weekly for four weeks, then climbs on a fixed schedule to a maintenance dose of 2.4 mg, or 1.7 mg for people who cannot tolerate the higher one^[1]. The escalation exists to limit gastrointestinal side effects, not to find the lowest dose that works. The trials measured weight change at the maintenance dose.

Zepbound is blunter. Its label sets the starting dosage at 2.5 mg once weekly for four weeks and then says the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage^[2]. Maintenance is 5, 10 or 15 mg, and 15 mg is the ceiling.

The trial record

The September 2026 search returned no human trial-tagged reports pairing microdosing with the specified GLP-1 terms. The identical filter with the GLP-1 terms removed returns 107 trial-tagged microdosing reports, which shows that the filter finds tagged papers, not that it captures all possible dosing research.

The search behind that zero. A PubMed search finds 0 results; the same search for microdosing of anything finds 107.

What does exist is clinicians writing about it. Two of the nine records are letters in Obesity and Diabetes Care from hospital pharmacy and endocrinology groups, on splitting doses out of multi-dose pens^[3][4]. They describe the practice, name the safety and accuracy questions, and don't report an outcome, because nobody has measured one.

The part that has produced actual harm reports

Microdosing usually means drawing a fraction of a dose yourself. The FDA has received multiple adverse event reports, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide — errors from patients measuring and self-administering the wrong amount, and in some cases from clinicians miscalculating^[5].

What sellers charge for a microdose

Sixteen sellers we review price a microdose as its own product. Where the same seller also publishes a full-dose price for the same named drug, the microdose is the cheaper line — which is the practical reason most people are offered one. NiceRx is the clearest example, and the table shows both of its lines side by side.

Microdose lines, beside the same seller's full-dose line where one exists

One of those lines never names a molecule at all, which means there's no full-dose price to compare it against on that seller's own page. Whether a company publishes what a single month costs, for every drug it sells, is the thing our grade is built on, and it's why a cheaper line isn't automatically a better deal.

Questions people actually ask